11.1 Assess and Analyze the Impact of Nutrition on the Cardiovascular System

Cholinergic drugs play a crucial role in treating myasthenia gravis, an autoimmune disorder affecting muscle strength. These medications work by enhancing acetylcholine activity at neuromuscular junctions, compensating for the reduced number of functional receptors in patients with the condition.

Understanding how cholinergic drugs function is key to grasping their effectiveness in managing myasthenia gravis symptoms. Nurses must be aware of proper administration, potential side effects, and the importance of patient education to ensure optimal treatment outcomes and patient safety.

Cholinergic Drugs in Myasthenia Gravis Treatment

Mechanism of cholinergic drugs

Top images from around the web for Mechanism of cholinergic drugs

• 

  Frontiers | New Insights Into Cholinergic Neuron Diversity View original

  Is this image relevant?

• 

  Neural Stimulation of Muscle Contraction | Biology for Majors II View original

  Is this image relevant?

• 

  Frontiers | The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing ... View original

  Is this image relevant?

• 

  Frontiers | New Insights Into Cholinergic Neuron Diversity View original

  Is this image relevant?

• 

  Neural Stimulation of Muscle Contraction | Biology for Majors II View original

  Is this image relevant?

1 of 3

Top images from around the web for Mechanism of cholinergic drugs

• 

  Frontiers | New Insights Into Cholinergic Neuron Diversity View original

  Is this image relevant?

• 

  Neural Stimulation of Muscle Contraction | Biology for Majors II View original

  Is this image relevant?

• 

  Frontiers | The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing ... View original

  Is this image relevant?

• 

  Frontiers | New Insights Into Cholinergic Neuron Diversity View original

  Is this image relevant?

• 

  Neural Stimulation of Muscle Contraction | Biology for Majors II View original

  Is this image relevant?

1 of 3

• Cholinergic drugs enhance activity of acetylcholine (ACh) at neuromuscular junction
  • ACh is neurotransmitter responsible for muscle contraction
• Cholinesterase inhibitors are primary cholinergic drugs used in myasthenia gravis treatment
  • Inhibit enzyme acetylcholinesterase (AChE), which breaks down ACh
  • Inhibiting AChE increases availability of ACh at neuromuscular junction (neostigmine, pyridostigmine)
• Increased ACh availability compensates for reduced number of functional ACh receptors in myasthenia gravis
  • Myasthenia gravis is autoimmune disorder characterized by production of antibodies against ACh receptors
• Cholinesterase inhibitors have rapid onset of action and relatively short duration of effect
  • Administered orally, with dosage adjustments based on individual patient response

Cholinergic System and Neurotransmission

• Autonomic nervous system regulates involuntary bodily functions
  • Parasympathetic nervous system is a branch that uses ACh as its primary neurotransmitter
• Neurotransmission occurs when ACh is released into the synaptic cleft
• ACh binds to cholinergic receptors on target cells to elicit a response

Cholinesterase inhibitors in treatment

• Indications:
  • Provide symptomatic treatment of myasthenia gravis
  • Improve muscle strength and reduce fatigue
  • Used in conjunction with immunosuppressive therapy (prednisone) and thymectomy
• Adverse effects:
  • Muscarinic effects: increased secretions (salivation, lacrimation, bronchial secretions), bradycardia, hypotension, gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal cramps)
  • Nicotinic effects: muscle fasciculations, muscle cramps, weakness
  • Central nervous system effects: restlessness, insomnia, headache, dizziness
• Drug interactions:
  • Anticholinergic drugs (atropine, glycopyrrolate) may antagonize effects of cholinesterase inhibitors
  • Aminoglycoside antibiotics (gentamicin) and neuromuscular blocking agents may potentiate effects of cholinesterase inhibitors
  • Succinylcholine, a depolarizing neuromuscular blocker, should be used with caution in patients taking cholinesterase inhibitors

Nursing considerations for cholinergic drugs

• Assess baseline muscle strength and monitor for improvement or deterioration
• Administer cholinesterase inhibitors at consistent times in relation to meals to optimize absorption and minimize gastrointestinal side effects
• Monitor for signs of cholinergic crisis (excessive cholinergic stimulation)
  1. Symptoms include increased muscle weakness, respiratory distress, excessive secretions, and bradycardia
  2. Cholinergic crisis requires prompt treatment with atropine and temporary discontinuation of cholinesterase inhibitors
• Monitor for signs of myasthenic crisis (severe exacerbation of myasthenia gravis)
  1. Symptoms include rapidly progressive muscle weakness, respiratory failure, and bulbar dysfunction (difficulty swallowing and speaking)
  2. Myasthenic crisis requires intensive care management, including respiratory support and immunomodulatory therapy (plasmapheresis, intravenous immunoglobulin)
• Educate patients and caregivers on proper administration, storage, and disposal of cholinesterase inhibitors
• Encourage patients to wear medical alert bracelet indicating their diagnosis and medication use

Patient education for cholinergic medications

• Explain purpose and mechanism of action of cholinesterase inhibitors in managing myasthenia gravis symptoms
• Instruct patients on proper medication administration, including timing in relation to meals and other medications
• Emphasize importance of consistent medication adherence and not altering doses without consulting healthcare provider
• Educate patients on common side effects and strategies for managing them (taking medications with food to minimize gastrointestinal disturbances)
• Teach patients and caregivers to recognize signs and symptoms of cholinergic crisis and myasthenic crisis and when to seek immediate medical attention
• Encourage patients to maintain medication log and bring it to all healthcare appointments
• Advise patients to inform all healthcare providers, including dentists, about their myasthenia gravis diagnosis and medication use
• Discuss importance of regular follow-up with healthcare team to monitor disease progression and adjust treatment as needed
• Provide resources for patient support groups (Myasthenia Gravis Foundation of America) and educational materials on myasthenia gravis and its management